Lastly, the study showed a decrease in MDK levels in 36 patients after tumor resection, followed by an elevation at the time of tumor recurrence, further supporting the notion that MDK could be a potent biomarker for disease progression monitoring as well. The gene discussed is MDK; the disease is neoplasm.